Bristol Myers Bets Big on Cell Therapy with Orbital Buy
Update: 2025-10-10
Description
Bristol Myers Squibb drops $1.5 billion to acquire Orbital Therapeutics, betting big on next-gen CAR-T therapy OTX-201 for autoimmune diseases and future growth beyond traditional drugs.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
